---
title: "Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References"
description: "Reference list for the formulary evidence report on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration. 50 cited documents."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References

<a id="references"></a>

## 5 References

1. [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)
2. [American Academy of Ophthalmology](https://www.aao.org/eye-health/drugs/anti-vegf-treatments)
3. [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)
4. [BrightFocus Foundation](https://www.brightfocus.org/macular/facts-figures/)
5. [CATT Research Group (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3157322/)
6. [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)
7. [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)
8. [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)
9. [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)
10. [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)
11. [Edison et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4285274/)
12. [Estreicher et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12912174/)
13. [Eyewire+ (2026)](https://eyewire.news/news/fda-approves-outlook-therapeutics-lytenava-as-first-ophthalmic-bevacizumab-for-wet-amd)
14. [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)
15. [Genentech LUCENTIS prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d)
16. [Genentech VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)
17. [Giustolisi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3516162/)
18. [Huang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534605/)
19. [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)
20. [Kozhevnikova et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9312436/)
21. [Kuzmina and Yakovlev (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12437679/)
22. [Li and Fekrat (2023)](https://www.retinalphysician.com/issues/2023/september/the-current-landscape-of-anti-vegf-biosimilars/)
23. [Lombardo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12532941/)
24. [Lucenteforte et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805632/)
25. [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)
26. [National Eye Institute wet AMD treatments page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/treatments-wet-amd-advanced-neovascular-amd)
27. [Outlook Therapeutics (2026)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-lytenava-fda-approval-as-the-first-and-only-fda-approved-ophthalmic-bevacizumab-for-the-treatment-of-wet-amd)
28. [Outlook Therapeutics FDA acceptance announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_ex99-1.htm)
29. [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)
30. [Outlook Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm)
31. [Outlook Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm)
32. [Outlook Therapeutics NORSE EIGHT complete twelve-week results press release (2025)](https://www.globenewswire.com/news-release/2025/01/16/3010622/0/en/Outlook-Therapeutics-Announces-Complete-Twelve-Week-Efficacy-and-Safety-Results-of-NORSE-EIGHT-Clinical-Trial.html)
33. [Outlook Therapeutics NORSE EIGHT preliminary topline results press release (2024)](https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_ex99-1.htm)
34. [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)
35. [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)
36. [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)
37. [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)
38. [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm)
39. [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)
40. [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)
41. [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)
42. [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)
43. [Regeneron EYLEA prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c)
44. [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)
45. [Review of Ophthalmology (2022)](https://www.reviewofophthalmology.com/article/retina-surgeons-share-their-treatment-preferences)
46. [Sambhara et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13413994/)
47. [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705084/)
48. [Somasundaran et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7754492/)
49. [Tran et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067424/)
50. [White et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8802008/)

## Related pages
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
